This Article
Right arrow Full Text (PDF)
Right arrow Letters to the Editor: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowReprints and Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by JOHNSON, R. W.
Right arrow Articles by LYFORD, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by JOHNSON, R. W., JR.
Right arrow Articles by LYFORD, J., III
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Technorati  
What's this?
Journal of Bone and Joint Surgery, 1945;27:557-561.
© 1945 by The Journal of Bone and Joint Surgery, Inc

TREATMENT OF BENIGN GIANT-CELL TUMOR IN THE LOWER THIRD OF THE FEMUR BY CURETTAGE AND "TELESCOPING" THE FRAGMENTS OF BONE

ROBERT W. JOHNSON JR. M.D.1 and JOHN LYFORD III M.D.1

1 Division of Orthopaedic Surgery, The Johns Hopkins Hospital, Baltimore

There has been described an operation for the conservative surgical treatment of benign giant-cell tumors in the distal end of the femur, in cases in which the articular cartilages of the knee joint are intact. This method permits removal of the tumor, and yet retains mobility of the knee joint and the full weight-bearing function of the leg. The procedure consists of obliterating the cavity by telescoping the fragments of bone, after removal of the tumor by curettage and chemical cauterization. To date the patients (all women) have accepted the shortening incurred, and have declined our offers to equalize length by operative shortening of the normal limb.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Technorati Technorati    What's this?